Skip to main content
ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,455.00
-30.00 (-1.21%)
At close: Nov 13, 2026

ImmuneOncia Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-111.21654.541107,73335.95
Revenue Growth
--83.01%495.04%-98.58%21413.29%1337.90%
Gross Profit
-14.3898.26643.4292.917,71628.15
Operating Income
-30,186-28,005-12,599-11,797-15,073-11,896
Net Income
-29,306-27,363-5,6878,864-3,492-60,490
Earnings Per Share
-385.23-389.65-101.00169.00-67.00-1302.00
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
93,17023,43811,32625,95726,73042,320
Total Debt
41.6569.5395.06136.94122.97314.63
Net Cash (Debt)
93,12823,36811,23125,82026,60742,005
Net Cash Growth
141.73%108.06%-56.50%-2.96%-36.66%103.58%
Net Cash Per Share
1224.17332.76199.46492.28510.53904.13

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-26,301-22,775-14,670-8,337-15,301-1,976
Capital Expenditures
-375.15-329.97-86.87-428.43-36.21-101.34
Free Cash Flow
-26,676-23,105-14,757-8,766-15,337-2,078
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-88.36%98.30%84.47%99.77%78.31%
Operating Margin
--25182.04%-1924.80%-10724.51%-194.91%-33093.66%
Pretax Margin
--24605.12%-868.86%8058.20%-45.15%-168272.99%
Profit Margin
--24605.12%-868.86%8058.20%-45.15%-168272.99%
FCF Margin
--20776.54%-2254.59%-7968.93%-198.32%-5779.96%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-8683.03----